- Home
- PLX vs CEE Comparison
PLX vs CEE Comparison
Compare PLX & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CEE
- Stock Information
- Founded
- PLX 1993
- CEE 1990
- Country
- PLX United States
- CEE Germany
- Employees
- PLX N/A
- CEE N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CEE Finance Companies
- Sector
- PLX Health Care
- CEE Finance
- Exchange
- PLX Nasdaq
- CEE Nasdaq
- Market Cap
- PLX 127.4M
- CEE 102.4M
- IPO Year
- PLX 1998
- CEE N/A
- Fundamental
- Price
- PLX $1.54
- CEE $17.29
- Analyst Decision
- PLX Strong Buy
- CEE
- Analyst Count
- PLX 1
- CEE 0
- Target Price
- PLX $15.00
- CEE N/A
- AVG Volume (30 Days)
- PLX 498.6K
- CEE 22.0K
- Earning Date
- PLX 08-14-2025
- CEE 01-01-0001
- Dividend Yield
- PLX N/A
- CEE 3.86%
- EPS Growth
- PLX N/A
- CEE N/A
- EPS
- PLX 0.05
- CEE N/A
- Revenue
- PLX $59,764,000.00
- CEE N/A
- Revenue This Year
- PLX $10.00
- CEE N/A
- Revenue Next Year
- PLX $83.13
- CEE N/A
- P/E Ratio
- PLX $32.18
- CEE N/A
- Revenue Growth
- PLX 0.18
- CEE N/A
- 52 Week Low
- PLX $0.82
- CEE $7.80
- 52 Week High
- PLX $3.10
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- PLX 53.22
- CEE 76.02
- Support Level
- PLX $1.41
- CEE $14.87
- Resistance Level
- PLX $1.52
- CEE $15.98
- Average True Range (ATR)
- PLX 0.06
- CEE 0.45
- MACD
- PLX 0.01
- CEE 0.13
- Stochastic Oscillator
- PLX 56.52
- CEE 95.28
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.